

Morningstar[®] Document ResearchSM

FORM 10KSB

HedgePath Pharmaceuticals, Inc. - HPPI

Filed: March 30, 2004 (period: December 31, 2003)

Annual report filed by small businesses

FORM 10-KSB

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Fiscal Year Ended December 31, 2003

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission file number: 001-13467

COMMONWEALTH BIOTECHNOLOGIES, INC.

(Name of small business issuer in its charter)

Virginia
(State or other jurisdiction of
incorporation or organization)

54-1641133
(I.R.S. Employer
Identification No.)

601 Biotech Drive
Richmond, Virginia 23235
(Address of principal executive offices) (Zip Code)

Issuer's telephone number: (804) 648-3820

Securities registered pursuant to Section 12(b) of the Act:
Common Stock, without par value per share

Securities registered pursuant to Section 12(g) of the Act:
None

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Check if there is no disclosure of delinquent filers in response to Item 405 of Regulation S-B contained in this form, and no disclosure will be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-KSB or any amendment to this Form 10-KSB .

The issuer's revenues for the year ended December 31, 2003 were \$ 5,104,056.

The aggregate market value of the shares of common stock, without par value ("Common Stock"), of the registrant held by non-affiliates on March 15, 2004 was approximately \$6.53 based on the closing sales price of the shares of \$ 4,685,027 per share, as reported on the NASDAQ Market on March 15, 2004.

As of March 15, 2004, there were 2,668,951 shares of Common Stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant's definitive proxy statement for its Annual Meeting of Shareholders to be held on May 14, 2004 are incorporated by reference into Part III of this Form 10-KSB.

Portions of the registrant's 2003 Annual Report to Shareholders are incorporated by reference into Part II of this Form 10-KSB.

Transitional Small Business Disclosure Format (check one:) Yes No .

PART I

Item 1. Description of Business.

Overview

Commonwealth Biotechnologies, Inc. (the “Company” or “CBI”) was founded in 1992 to provide sophisticated research and development support services on a contract basis to the biotechnology industry. The Company’s customers consist of private companies, academic institutions and government agencies, all of which use biological processes to develop products for research, health care, agricultural, and other purposes. The Company’s revenues are derived principally from providing macromolecular synthetic and analytical services to researchers in the biotechnology industry or to researchers who are engaged in life sciences research in government or academic labs throughout the world.

The Company provides these services to customers on a contract basis and derives its revenues from these services, and not only from sales of commercial products resulting from the research. This arrangement distinguishes the Company from many other biotechnology companies in that the Company’s revenues are not derived from successful commercialization of a new biotechnology product. The Company has developed a strong reputation as a leading provider of biotechnology research and development analytical services and in particular, has positioned itself as a leading provider of fundamental programs as they relate to bio-defense. The Company is focusing its expansion efforts on increasing its long-term relationships with customers in the private sector biotechnology companies, in major pharmaceutical companies, and in comprehensive government programs. The Company continues to keep pace with new technologies and is able to offer these new services to its customers. In particular, the Company is focused on providing its technology offerings under strict Good Laboratory Practices (GLP) guidelines, which makes the Company very attractive to those entities, which require assurance that the work done is of the highest quality possible.

The Company’s approach to providing services is called “Concept-to-Clinic” and is the key to CBI’s continued success. It defines the approach taken with all clients – design, development, implementation and testing. Whether the client is a start-up company with research and development needs, or an established firm wishing to move a product through clinical regulation, CBI stands ready as partner of choice to provide the required services that ensures success. The use of Concept-to-Clinic is evidenced in the broad array of services CBI offers its clients.

Growth Strategy

The Company’s strategy for growth focuses on expanding its long term contracts in three principal areas; bio-defense, comprehensive platform technology programs, and in laboratory support for on-going clinical trials. The Company is not currently pursuing scientific improvements to its intellectual property portfolio, but has been awarded US and foreign patents and trademark protection for several of its intellectual properties, including Accutrac™, Accutrac-P™, HepArrest™, cationic-helix endotoxin binding peptides, and a novel viral reverse-transcriptase assay. Other patents are still pending, including protection for CBI’s unique herpes virus assay platform.

CBI continues to grow its bio-defense contract business. CBI is now in its fifth year of a subcontract program from the IIT Research Institute on behalf of a government sponsor. This program is for protocol development work in the general area of bio-defense. CBI is the prime contractor for a second government sponsor under which CBI has developed novel molecules associated with nefarious bio agents. CBI is also the prime contractor with yet another government agency for developing and novel methods of DNA sequence analysis to facilitate bio-agent strain identity. CBI is also the named subcontractor to a private

sector client under which samplings are received daily at CBI from mail sorting facilities. CBI is tasked with analysis of these samples for the presence of potentially lethal bio-agents. In the past year, CBI has successfully executed several high dollar contracts in the general area of vaccine development for particular select agents and additional contracts in this area are pending. In addition, CBI is the prime or subcontractor on numerous pending bio-defense related contracts.

CBI has thus found a niche in bio-defense because it is able to offer efficient, state-of-the-art analyses to our customers in a time and cost competitive fashion, in a secure, classified facility. These contracts demonstrate the high regard with which the various governmental agencies view CBI and are acknowledgements of its expertise in the complex area of detection and identification of agents that may be used in bio-warfare.

CBI continues to expand its molecular diagnostics platforms, in particular in support of different human clinical trials. In the ideal scenario, a client comes to CBI with the need to first design and then implement a unique molecular assay for his clinical product. CBI then designs, implements, tests and validates the new assay for its client. Once validated, patient samples acquired in the course of a clinical trial are sent to CBI for analysis. CBI is in the midst of three such programs where CBI initially designed, implemented, and then validated the assay protocol. Patient samples are now routinely analyzed by these assays at CBI.

In addition, CBI continues to assay patient samples received from around the country for the presence of DNA attributable to the various human Herpes viruses. CBI's platform offers rapid analysis combined with single copy sensitivities. Similarly, CBI is now actively engaged in performance of various assays, which are part and parcel of the QC process for validating new experimental vaccines. CBI is uniquely qualified to do this work in light of its rigorous adherence to compliance requirements and its robust array of fundamental technology offerings.

CBI is making a concerted effort to enhance its comprehensive contract backlog, particularly in the private sector. CBI's marketing efforts in this regard include on-site visits and direct calls and mailings. CBI's revitalized marketing activities in 2003 were made possible by a private placement completed in late 2002.

Other areas for the Company's growth include:

- Overexpression and characterization. The Company believes that there is a pressing need for GLP rated facilities to perform validated assay work on new recombinant products for large and small biotech companies. CBI is currently performing such work under long-term contracts to different industry clients.
- Reference Lab Work. CBI continues to grow its reference lab DNA work, which encompasses human paternity testing and CODIS data base analysis. CBI is one of 9 qualified vendors eligible to compete for block funds issued to the states by the National Institute of Justice. CBI successfully competed for a state contract for Combined DNA Index System (CODIS) data base work and expects to compete for the next round of funds to be released in the area of forensic sample analysis.
- Microbiology. Working individually or teamed with industry partners, CBI offers traditional and cutting edge microbiological analyses. Current clients include those looking to confirm the presence of suspected pathogens in suspicious powders. CBI also is consulting with major food providers to put in place rapid and meaningful assays and surveys for food borne pathogens.
- Genomics/Proteomics. As the DNA make-up of individual organisms (including humans) is unveiled, CBI is able to help identify and characterize the proteins that make up the "proteome" encoded by the DNA. The Company believes that its genomics and proteomics capabilities are well recognized and has received to contracts Illinois Institute of Technology Research Institute (IITRI) in pursuit of these studies. The National Cancer Institute funds both contracts. CBI specializes at developing novel mass spectral methods for characterization of organismal proteomes.

Regulatory Compliance

The Company is registered under the Clinical Laboratories Improvement Act (CLIA) that enables the Company to accept human samples for analysis and to perform analysis of human clinical samples for the presence of known genetic markers.

The Company is also accredited under the guidelines of the National Forensic Science Technology Center, (NFSTC), to perform DNA identity testing for submission of data into the Combined DNA Index System (CODIS) data base, and is one of a select few commercial facilities nationwide accredited by the NFSTC to perform criminal (felony) DNA database testing for submission into the FBI CODIS database.

The American Association of Blood Banks (AABB) accredits the Company, and the Company has participated in a validation study through the College of American Pathologists (CAP). Accreditation by the AABB enables the Company to perform paternity testing on private and public cases.

The Company is also accredited by the Centers for Disease Control to receive and handle select agents. The Company operates and maintains an accredited Biosafety level 3 facility.

The Company operates under strict GLP (Good Laboratory Practices) guidelines and has been successfully audited by a number of private companies and governmental agencies.

These various accreditations enhance the Company's position in the marketplace and bolster its "Concept-to-Clinic" offerings. In addition to managing clinical trial work, the Company has the capacity to perform the associated lab services and the results of these lab analyses will be acceptable to the regulatory authorities.

Strategies for improving CBI's contract business

CBI re-organized its management structure in 2002 and re-assigned some duties and responsibilities of senior management to various senior scientific staff members. This move has enabled Dr. Harris, Dr. Freer and Mr. Reynolds to become more actively involved in the early interaction with potential clients and development of new business, especially as it pertains to classified research efforts. Dr. Harris assumed the responsibilities of Chief Executive Officer (CEO) in addition to his duties as President. This is in keeping with his strengths in interacting very positively with potential clients and facilitated CBI's expanded bio-defense contract position. Dr. Freer assumed the responsibilities of Chief Operating Officer (COO) in addition to his duties as Chair of the Board of Directors. This move consolidated his current oversight of marketing, sales, compliance, safety, and drug development services under one organizational entity and has greatly bolstered CBI's compliance expertise. The DNA laboratories were re-organized at the end of 2001 that allowed Mr. Reynolds more time to fully participate in strategic marketing and business development activities.

In October 2002, CBI hired Mr. Charles R. Waldrige as Senior Vice President for Strategic Business Development. Mr. Waldrige has been steadily working towards bringing new comprehensive research contracts to CBI principally from the private pharmaceutical sector.

The focus of CBI's revitalized marketing efforts are to develop new, long-term contracts and business relationships with pharmaceutical, biotech, research companies, and government labs.

Analytical Support Services

The Company is a fee-for-service contractor offering integrated programs that span the gamut of state-of-the-art life sciences investigations. Typically, the Company takes no ownership position in the intellectual property rights resulting from services it performs under contract for its customers. Since commencing operations, the Company has become noted for providing a wide range of services relating to design, synthesis, purification, and analysis of peptides, proteins, and oligonucleotides and in creating unique assay and detection methods.

CBI's competitive edge resides in its ability to provide a wide range of services in fully integrate research programs. There are few major competitors which offer integrated DNA/RNA and protein/peptide technologies and none that offer these technologies combined with sophisticated biophysical analytical techniques, such as calorimetry, spectroscopy, and mass spectral analysis. Thus, the Company can provide complete research programs to its customers. "One stop biotechnology shopping" has proved attractive in securing long-term contracts with customers ranging from major pharmaceutical industry researchers to major government sponsors of research, including agencies of the Department of Defense.

The services offered by the Company are fully detailed in its promotional brochures, and on its World Wide Web page. The Company offers "fax-on-demand" for customers who seek technology descriptions and pricing information.

Customers

CBI has successfully re-defined its client base to focus on long-term project goals, rather than on individual orders for selected technologies. "Concept-to-Clinic" defines the approach taken with all clients – design, development, implementation and testing. CBI's clients are from private companies, academic institutions and government agencies across the globe. Whether the client is a start-up company with research and development needs, or an established firm wishing to move a product through the regulatory process, CBI stands ready as partner of choice to provide the required services that ensure success.

Over the years, CBI has re-priced its platform technologies to maintain its margins while maintaining its competitive edge. In several instances, CBI ceased to offer a technology service when it became clear that the price needed to pay its overhead and maintain its margin made CBI non-competitive in the market place. CBI management continuously reviews its pricing policies.

Operations

Requests for quotes from potential customers are received via phone, e-mail, from the Company's World Wide Web page, or by hard copy directed to the Company's business coordinator or laboratory manager. All inquiries are answered by direct mail of the Company brochure and price lists, with follow up phone calls, where appropriate. Price quotes for small projects or scientists who possess the expertise necessary to respond appropriately generate routine analytical procedures. The Company personnel having the requisite expertise develop quotes for more complex projects collaboratively. Most quotations are sent back to the inquiring scientist within one working day.

Incoming orders are logged onto the Company's project management system, assigned a work order number, and delivered to the appropriate scientist designated to oversee and coordinate all aspects of the particular project. The work to be done is scheduled on the appropriate instruments, and all necessary reagents or other supplies needed to complete the project are ordered as needed. Every customer is required to sign a service agreement prior to the Company initiating any requested work.

As a commercial contract is completed, progress reports are usually sent to the customer detailing the results found to date, and the conclusions to be drawn. If the project is relatively straightforward, such as an amino acid analysis, spectroscopy, or DNA sequence analysis, the results are faxed or e-mailed to the customer prior to sending the customer the hard copy of the results. If the project involves a synthesis of a peptide or oligonucleotide, for example, the product is sent to the customer by express mail service. A data sheet accompanies every product, which details the physicochemical properties of the compound, including the results of all analytical tests performed, which supports the claimed purity and composition. The customer is invoiced upon completion of the work, or at particular points in the work program. The customer pays for the analytical services provided in accordance with the Company's standard fee structure and typically retains all rights to any intellectual property resulting from the analysis.

All data generated at the Company are archived for the customer. Where appropriate, the data are archived on selected storage media, such as back up tapes or computer disks. A file is maintained for every customer, and these files are also archived. The Company employs appropriate security measures to ensure the confidentiality of customer information.

The Company operates under strict Standard Operating Protocols (SOPs) that detail the particular technologies used to complete the work in progress. The Company's technical team follows standard operating procedures, which help to produce consistent, high quality results.

Proprietary Research and Development

CBI has developed its own intellectual properties that could potentially add a significant revenue stream to the company when they are fully commercialized. However, CBI is focused entirely on its core competencies and as such, has more or less abandoned development of intellectual properties. CBI's focus with regard to its patent portfolio is to find third party licensees who can fully exploit a product's potential.

The Company takes appropriate steps to protect its intellectual property rights and those of its customers. The Company's practice is to require its employees and consultants to execute non-disclosure and proprietary rights agreements upon commencement of employment or consulting arrangements with the Company. These agreements acknowledge the Company's exclusive ownership of all intellectual property developed by the individual during the course of his work with the Company and require that all proprietary information disclosed to the individual by the Company or its customers remain confidential.

Marketing

The Company has expanded its customer base primarily through word-of-mouth referrals, attendance at a limited number of trade shows, seminars, and on-site meetings with decision makers. Because of its ability to offer a wide range of biotechnology research services, the Company enjoys a favorable reputation among its customers, and many new customers come to the Company by word-of-mouth recommendation. The Company has constructed its own World Wide Web Home Page (www.cbi-biotech.com) and is listed with several bio-technical and biomedical oriented sites on the World Wide Web.

Human Resources

The Company currently has 34 full time employees including 5 employees in administration, marketing, sales, and customer relations, 1-computer network specialists, and 27 employees in laboratory operations. 10 of the Company's employees hold doctorate degrees, and 6 have master's degrees. None of the Company's employees are represented by a labor union. The Company has experienced no work stoppages and believes its relations with its employees to be good.

Competition

The Company faces several types of competition. The Company believes there are fewer than 25 companies who can be considered competitor for individual technologies and fewer than 5 companies who can be considered competitors for multiple technologies. Virtually no other companies, offers the breadth of CBI's services, especially with regard to its expertise in bio-defense related work.

Government Regulation

The Company does not require government regulatory approvals to provide its current services. Numerous federal, state and local agencies, such as environmental, working condition and other similar regulators, have jurisdiction to take action that could have a material adverse effect upon the Company's ability to do business. The Company believes that it is in general compliance with existing federal, state and local laws and regulations and does not anticipate that continuing compliance will have any material effect upon the capital expenditures, earnings or competitive position of the Company.

The Company anticipates that its pursuit of its growth strategy will subject the Company to a heightened level of government regulation of its operations. For example, in pursuing opportunities to provide analytical services to customers seeking the approval of the United States Food and Drug Administration (FDA) of products, the Company's operations will become subject to compliance with standards established by the FDA, including inspections by the FDA and other federal, state and local agencies regarding work performed by the Company on specific FDA submission projects. If significant violations are discovered during an inspection, the Company may be restricted from undertaking additional work on projects until the violations are remedied. The Company has a license from the Nuclear Regulatory Commission (NRC) for conduct of work involving radionuclides and operates a BSL3 facility under accreditation from the Centers for Disease Control.

Item 2. Description of Property.

Facilities

Construction of the Company's present facility was completed in November 1998 at an overall cost of approximately \$ 5.1 million financed primarily through the Virginia Small Business Financing Authority (VSBFA) that issued \$ 4,000,000 in tax-exempt industrial revenue bonds (IRBs) for the benefit of the Company. As of December 31, 2003, the aggregate principal amount of the outstanding IRBs was approximately \$ 3,730,000. In connection with the IRB financing, liens were placed on the facility and substantially all of the Company's assets, including its accounts receivables. The Company possesses a limited right to prepay the IRB obligations pursuant to the terms of the Loan Agreement attached as Exhibit 10.14 to this Annual Report on Form 10-KSB. The debt associated with the IRBs amortizes as follows:

<u>Principal Amount Due (\$)</u>	<u>Date Due</u>	<u>Applicable Interest Rate (%)</u>
85,000	March 15, 2001	5.2
90,000	March 15, 2002	5.3
95,000	March 15, 2003	5.4
100,000	March 15, 2004	5.5
105,000	March 15, 2005	5.6
110,000	March 15, 2006	5.7
115,000	March 15, 2007	5.8
125,000	March 15, 2008	5.9
130,000	March 15, 2009	6.0
140,000	March, 15, 2010	6.1
145,000	March 15, 2011	6.2
155,000	March 15, 2012	6.3
2,275,000	March 15, 2022	7.0
330,000	March 15, 2023	8.0

The Company's facility, located in Richmond, Virginia, encompasses 32,000 square feet of state-of-the-art laboratory and administrative space. The building is designed to facilitate movement of samples throughout each laboratory, and where necessary, to maintain and ensure custody of samples. The building houses expansion space, which was purposefully left undeveloped to accommodate new technologies as they come on board. The Company took possession of its current facility in late November 1998, and all labs were fully operational in the facility by mid December 1998. The Company believes that the facility is adequately insured.

Item 3. Legal Proceedings.

The Company incurred no legal matters in 2003.

Item 4. Submission of Matters to a Vote of Security Holders.

No matter was submitted to a vote of security holders in the fourth fiscal quarter of 2003.

PART II

Item 5. Market for Common Equity and Related Stockholder Matters.

The information set forth on page 5 the Company's 2003 Annual Report to Shareholders under the caption "Market for Common Equity" is incorporated herein by reference.

The following table provides information about our equity compensation plans as of December 31, 2003:

	a	b	c
Plan Category	Number of securities to be issued upon exercise of outstanding options, warrants and rights	Weighted-average exercise price of outstanding options, warrants and rights	Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
Equity compensation plans approved by security holders	728,683	\$ 5.03	168,126
Equity compensation plans not approved by security holders	0	0	0
Total	728,683	\$ 5.03	168,126

Item 6. Management's Discussion and Analysis or Plan of Operation.

The information set forth on pages 6 through 17 of the Company's 2003 Annual Report to Shareholders under the caption "Management's Discussion and Analysis of Financial Condition and Results of Operations" is incorporated herein by reference.

Item 7. Financial Statements.

The Company's financial statements and the related notes thereto, together with the report of BDO Seidman LLP for 2003 and McGladrey & Pullen, LLP for 2002, set forth on pages 18 through 38 of the Company's 2003 Annual Report to Shareholders are incorporated herein by reference.

Item 8. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

McGladrey and Pullen ("McGladrey") served as the Company's independent public accountants for the fiscal years ended December 31, 1998, December 31, 1999, December 31, 2000, December 31, 2001 and December 31, 2002. For various business reasons, McGladrey opted to resign as the Company's auditors on June 15, 2003. McGladrey's reports on the Company's financial statements for each of the last five fiscal years did not contain an adverse opinion or disclaimer of opinion. Similarly, McGladrey did not modify either such report as to uncertainty, audit scope or accounting principles. There were no disagreements between the Company and McGladrey regarding any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure.

The Company is not presently involved in any disagreements with its independent auditors on accounting financial disclosures.

Item 8A. Controls and Procedures.

The Company's Chief Executive Officer and Controller (principal executive officer and principal financial officer, respectively) have concluded, based on their evaluation as of December 31, 2003, that the design and operation of the Company's "disclosure controls and procedures" (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended ("Exchange Act")) are effective to ensure that information required to be disclosed by the Company in the reports filed or submitted by the Company under the Exchange Act is accumulated, recorded, processed, summarized and reported to management, including the Company's principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding whether or not disclosure is required.

During the quarter ended December 31, 2003, there were no changes in the Company's "internal controls over financial reporting" (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect the Company's internal controls over financial reporting.

PART III

Item 9. Directors, Executive Officers, Promoters and Control Persons; Compliance with Section 16(a) of the Exchange Act.

Directors

The information relating to the directors of the Company set forth in the Company's definitive proxy statement relating to the Company's Annual Meeting of Shareholders to be held on May 14, 2004 (the "Proxy Statement") under the caption "Proposal 1: Election of Directors" is incorporated herein by reference.

Executive Officers

The information relating to the executive officers of the Company set forth in the Proxy Statement under the caption "Executive Compensation – Executive Officers of the Company" is incorporated herein by reference.

Compliance with Section 16(a) of the Securities Exchange Act of 1934

The information relating to compliance with Section 16(a) of the Securities Exchange Act of 1934, as amended, set forth in the Proxy Statement under the caption "Section 16(a) Beneficial Ownership Reporting Compliance" is incorporated herein by reference.

Code of Conduct

The information relating to the Company's Code of Conduct is set forth in the Proxy Statement under the caption "Code of Conduct" is incorporated herein by reference.

Item 10. Executive Compensation.

The information set forth in the Proxy Statement under the caption "Executive Compensation" is incorporated herein by reference.

Item 11. Security Ownership of Certain Beneficial Owners and Management.

The information set forth in the Proxy Statement under the caption "Voting Securities and Principal Holders Thereof" is incorporated herein by reference.

Item 12. Certain Relationships and Related Transactions.

The information set forth in the Proxy Statement under the caption "Certain Relationships and Related Transactions" is incorporated herein by reference.

Item 13. Exhibits and Reports on Form 8-K.**(a) Exhibits**

<u>Exhibit Number</u>	<u>Description of Exhibit</u>
3.1	Amended and Restated Articles of Incorporation (1)
3.2	Amended and Restated Bylaws (1)
4.1	Form of Common Stock Certificate (1)
4.2	Form of Underwriter's Warrant, as amended (1)
4.3	Form of Management Warrant, as amended (1)
10.1	Placement Agreement by and between the Company and Anderson & Strudwick, Incorporated ("A&S") (1)
10.2	Warrant Agreement between the Company and A&S (1)
10.3	Warrant Agreement between the Company and Richard J. Freer, as amended (1)
10.4	Warrant Agreement between the Company and Thomas R. Reynolds, as amended (1)
10.5	Warrant Agreement between the Company and Robert B. Harris, as amended (1)
10.6	Employment Agreement for Richard J. Freer (1)
10.7	Employment Agreement for Thomas R. Reynolds (1)
10.8	Employment Agreement for Robert B. Harris (1)
10.9	Executive Severance Agreement for Richard J. Freer (1)
10.10	Executive Severance Agreement for Thomas R. Reynolds (1)
10.11	Executive Severance Agreement for Robert B. Harris (1)
10.12	1997 Stock Incentive Plan, as amended (1)
10.13	2000 Stock Incentive Plan (3)
10.14	2002 Stock Incentive Plan (4)
10.15	Loan Agreement between the Company and the Virginia Small Business Financing Authority (2)
10.16	Employment Agreement for James H. Brennan (5)
10.17	Executive Severance Agreement for James H. Brennan (5)
13.1	Annual Report to Shareholders for the Fiscal Year Ended December 31, 2003 incorporated in Form 10-KSB (6)
23.1	Letter of Consent from McGladrey & Pullen LLP (6)
31.1	Certification of Robert B. Harris, Ph.D. (6)
31.2	Certification of James H. Brennan (6)
32.1	Section 906 Certification of Robert B. Harris, Ph.D. (6)
32.2	Section 906 Certification of James H. Brennan (6)

- (1) Incorporated by reference to the Company's Registration Statement on Form SB-2, Registration No. 333-31731.
(2) Incorporated by reference to the Company's Current Report on Form 8-K, dated April 6, 1998, File No. 001-13467.
(3) Incorporated by reference to the Company's Registration Statement on Form S-8, Registration No. 333-51074.
(4) Incorporated by reference to the Company's Registration Statement on Form S-8, Registration No. 333-102368.
(5) Incorporated by reference to the Company's Annual Report on Form 10-KSB, dated March 31, 2003.
(6) Filed herewith.

Executive Compensation Plans and Arrangements

The following is a list of all executive compensation plans and arrangements filed as exhibits to this annual report on Form 10-KSB or incorporated herein by reference:

1. Warrant Agreement between the Company and Richard J. Freer, as amended (1)
 2. Warrant Agreement between the Company and Thomas R. Reynolds, as amended (1)
 3. Warrant Agreement between the Company and Robert B. Harris, as amended (1)
 4. Employment Agreement between the Company and Richard J. Freer (1)
 5. Employment Agreement between the Company and Thomas R. Reynolds (1)
 6. Employment Agreement between the Company and Robert B. Harris (1)
 7. Employment Agreement between the Company and James H. Brennan (2)
 8. Executive Severance Agreement between the Company and Richard J. Freer (1)
 9. Executive Severance Agreement between the Company and Thomas R. Reynolds (1)
 10. Executive Severance Agreement between the Company and Robert B. Harris (1)
 11. Executive Severance Agreement between the Company and James H. Brennan (2)
 12. 1997 Stock Incentive Plan (1)
 13. 2000 Stock Incentive Plan (3)
 14. 2002 Stock Incentive Plan (4)
-
- (1) Previously filed as an exhibit to the Company's Registration Statement on Form SB-2, Registration No. 333-31731, and incorporated by reference herein.
 - (2) Previously filed as an exhibit to the Company's Annual Report on Form 10-KSB, dated March 31, 2003.
 - (3) Previously filed as an exhibit to the Company's Registration Statement on Form S-8, Registration No. 333-51074, and incorporated by reference herein.
 - (4) Previously filed as an exhibit to the Company's Registration Statement on Form S-8, Registration No. 333-102368, and incorporated by reference herein.

(b) Reports on Form 8-K

On October 14, 2003, the Company filed on Form 8-K relating to the Company's financial performance.

Item 14. Principal Accountant Fees and Services.

The information set forth in the Proxy Statement under the caption "Appointment of Independent Auditors" is incorporated herein by reference.

SIGNATURES

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

COMMONWEALTH BIOTECHNOLOGIES, INC.

Date: March 30, 2004

By: /s/ Robert B. Harris, Ph.D.

Robert B. Harris, Ph.D.
President

In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

<u>Name</u>	<u>Title(s)</u>	<u>Date</u>
<u>/s/ Richard J. Freer, Ph.D.</u> Richard J. Freer, Ph.D.	Chairman, COO and Director (Principal Executive Officer)	March 30, 2004
<u>/s/ Robert B. Harris, Ph.D.</u> Robert B. Harris, Ph.D.	President, CEO and Director	March 30, 2004
<u>/s/ Thomas R. Reynolds</u> Thomas R. Reynolds,	Executive Vice President, Secretary and Director	March 30, 2004
<u>/s/ James H. Brennan</u> James H. Brennan	Controller (Principal Financial and Accounting Officer)	March 30, 2004
<u>/s/ James. P. Causey</u> James P. Causey	Director	March 30, 2004
<u>/s/ Samuel P. Sears, Jr.</u> Samuel P. Sears, Jr.	Director	March 30, 2004
<u>/s/ Dr. Donald McAfee</u> Dr. Donald McAfee	Director	March 30, 2004
<u>/s/ Peter C. Einselen</u> Peter C. Einselen	Director	March 30, 2004

**To the Shareholders of
Commonwealth Biotechnologies, Inc.**

This past year was a year of firsts for CBI; a record number of contracts, the first year in which signed contract volume totaled more than a record \$7 million, the first year in which the Company was awarded a CODIS data base contract, and the first year in which CBI showed a net profit (albeit only a modest profit) for two consecutive quarters. CBI has been cash positive and EBITDA positive for the past two years.

In 2003, CBI initiated discussions on several new business initiatives, one of which has just recently come to fruition. These initiatives can be directly attributed to the hard work and persistence of its revitalized marketing activities, which were made possible by a private placement completed in 2002. Hence, CBI announced execution of a unique Broad Teaming Agreement with Dynport Vaccine Co., LLC, Frederick, MD, under which CBI and Dynport will co-venture wherever appropriate to compete for new monies in bio-defense and vaccine development.

Dynport is a joint venture of DynCorp, a CSC company, and Porton International Inc whose charge is to ensure the safety of U.S. operating forces through the advanced development and manufacture of biodefense related products, in particular, vaccines directed towards bio-threat agents. DVC provides an integrated approach for the advanced development of specific vaccines and other products to protect our nation against the threat of bio-warfare agents. This development effort includes process refinement, cGMP production, non-clinical testing, clinical evaluation and successful submission of Biologics License Applications to the Food and Drug Administration (FDA). Dynport and CBI have a long-standing and extremely successful relationship wherein CBI has already provided Dynport with key research, development, and production capabilities in support of Dynport's many bio-defense related programs. Dynport and CBI are also currently teamed on no less than six major contract proposals valued at more than \$30 million which are pending review at the various sponsoring agencies. In the past year alone, revenues realized by CBI, in pursuit of Dynport contracts has exceeded \$ 1.2 million. In signing the Agreement, CBI and Dynport acknowledged their complementary expertise and capabilities in the performance of life sciences contract research programs as they relate to on-going bio-defense initiatives. At present, Dynport is focused in several areas, including development of vaccines directed against Anthrax, Botulinum, Plague, Staphylococcal Enterotoxin, Tularemia, Smallpox, and Venezuelan Equine Encephalitis.

But perhaps the most exciting aspect of 2003 was the dramatic improvement in the Company's fiscal position. At year-end, the Company reported a modest profit for the fourth quarter, which was the second consecutive quarter of profitability. For the fourth quarter, in terms of net earnings, the Company showed a positive swing of about \$400,000, compared to the same period in 2003. For the year 2003, the Company recorded a loss of approximately \$81,000 on \$5.1 million in gross sales, compared to a loss in 2002 of \$626,000 on \$4.4 million in gross sales. Of equal importance, the


Company realized positive cash flows from operations of approximately \$240,000 and was EBITDA positive for the second consecutive year. The 2003 EBITDA calculation of \$776,412 is shown below:

2003 EBITDA Calculation


Net Loss	\$ (80,601)
Add: Interest and Amortization	258,249
Depreciation	598,764
Taxes	—
EBITDA	\$776,412

CBI continues to show positive growth in gross revenues while simultaneously shrinking its net operating loss. Over the last 6 years, since its IPO in 1997, CBI's overall gross revenues have increased nearly 200% and its net operating losses have decreased nearly 90%. Interestingly, while the majority of our clients are in the private sector, the bulk of our revenues are currently derived from government sources. We hope to equalize this distribution of revenues by increasing the number and magnitude of contract with commercial clients. Graphically, these trends are shown in the figures below. While there is still progress to be made, we look forward to an even better year in 2004!

REVENUE DISTRIBUTION - 2003




GROSS REVENUES FOR THE PERIOD 1997 – 2003



* Revenue in 2001 includes a one-time license fee payment of \$ 400,000

P & L FOR THE PERIOD 1997 - 2003



Thank You for Your Continued Support

CBI is doing a better job of communicating progress to its shareholders. Through press releases and 8-K announcements, CBI has informed its shareholders of new contract signings and significant milestones in the Company's operations. The Company's progress in all areas this past year has resulted in increasing the value of the Company's stock, but management still believes the Company is undervalued. In 2004, we will continue to explore all possible ways of enhancing shareholder value.

CBI's employees continue to increase individual and collective productivity. We have signed a record number of contracts *without significantly increasing staff*. Our ability to do this directly contributes to the bottom line by helping to hold a tight line on expenses. The fact that we are asked to team with industry partners in pursuit of high dollar contract proposals is directly related to the professionalism and expertise of our employees. Thanks to one and all.

You are cordially invited to attend CBI's 2004 Annual Meeting of Shareholders on May 14, 2004 at 11:00 a.m. at the Company's facility.

With best regards,

Richard J. Freer, Ph.D.
Chairman of the Board, COO

Robert B. Harris, Ph.D.
President, CEO

Thomas R. Reynolds
Executive Vice-President,
Science and Technology

James H. Brennan
Controller

CBI welcomes your calls and inquiries.

Phone: 800-735-9224
Fax: 804-648-2642
E-Mail: info@cbi-biotech.com
Web: www.cbi-biotech.com
Address: 601 Biotech Drive
Richmond, VA 23235

Stockholder Matters

Market for Common Equity

The Company completed its initial public offering on October 28, 1997 at a price per share of \$6.00. Since that time, the common stock has traded on the NASDAQ SmallCap Market ("NASDAQ"). The following table sets forth the range of high and low sales price per share of common stock for 2003 and 2002. These market quotations reflect inter-dealer prices, without retail mark-up, mark-down, or commission and may not necessarily represent actual transactions.

<u>Period</u>	<u>High Stock Price</u>	<u>Low Stock Price</u>
1 st Quarter, 2003	\$ 2.52	\$.54
2 nd Quarter, 2003	\$ 2.26	\$ 1.01
3 rd Quarter, 2003	\$ 4.21	\$ 1.44
4 th Quarter, 2003	\$ 4.08	\$ 2.60
<u>Period</u>	<u>High Stock Price</u>	<u>Low Stock Price</u>
1 st Quarter, 2002	\$ 2.97	\$ 1.65
2 nd Quarter, 2002	\$ 1.99	\$ 1.23
3 rd Quarter, 2002	\$ 1.40	\$.57
4 th Quarter, 2002	\$ 1.15	\$.37

On March 15, 2004, the last reported sales price for a share of the Company's Common Stock on NASDAQ was \$6.53. As of March 14, 2004 there were 41 holders of record of the Company's Common stock and 1,667 beneficial holders.

The Company has not paid any cash dividends on its Common Stock. The Company intends to retain its earnings to finance the growth and development of its business and does not expect to declare or pay dividends in the foreseeable future. The declaration of dividends is within the discretion of the Company. However, the Company's ability to pay dividends may be constrained by certain provisions of its industrial revenue bond financing.

Selected Financial Data

Set forth below is selected financial data with respect to the Company for the years ended December 31, 2003, December 31, 2002, and December 31, 2001, which has been derived from the audited financial statements of the Company. The selected financial data set forth below should be read in conjunction with "Management's Discussion and Analysis of Financial Conditions and Results of Operation."

	For the years Ended December 31,		
	2003	2002	2001
Operational Data:			
Revenues:	\$5,104,056	\$4,434,379	\$ 4,786,087
Net Loss	\$ (80,601)	\$ (625,726)	\$(1,673,031)
Basic and diluted loss per common and common equivalent share	\$ (0.03)	\$ (0.29)	\$ (0.81)
Weighted average common shares outstanding	2,486,699	2,194,029	2,076,164
Balance Sheet Data:			
Total Current Assets	\$1,155,839	\$ 838,687	\$ 817,046
Total Assets	\$7,581,213	\$7,823,073	\$ 8,348,718
Total Current Liabilities	\$ 579,920	\$ 751,986	\$ 803,638
Total Liabilities	\$4,209,920	\$4,481,986	\$ 4,693,949
Total Stockholders equity	\$3,371,293	\$3,341,087	\$ 3,654,769

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following should be read in conjunction with "Selected Financial Data" and the Company's Audited Financial Statements and Notes thereto included herein.

Overview

The Company's revenues are derived principally from providing macromolecular synthetic and analytical services to researchers in the biotechnology industry or who are engaged in life sciences research in government or academic labs throughout the world. Development of innovative technologies for biotechnology requires sophisticated laboratory techniques and the Company provides these services to customers on a contract basis. The Company's customers consist of private companies, academic institutions and government agencies, all of which use biological processes to develop products for health care, agricultural, and other purposes.

The Company generally derives revenue from two types of customers: those who require a discrete set of services ("lab services"), and those who contract with the Company on an extended basis for performance of a variety of services (commercial contracts, and government contracts). The Company continues to grow its defense contract business and is now actively engaged in all areas in bio defense related work. The Company acts as both prime and subcontractor for bio defense related work.

More often than not, the Company's customers provide repeat business to the Company. The Company views commercial, drug development, and government contracts as the more important sources of revenue. The Company has continued to focus its efforts on identifying these customers. These contracts generally range from a few months to more than a year. Revenues are generally recognized as services are rendered or as products are delivered. In addition, revenue is also recognized with performance-based installments payable over the contract as milestones are achieved.

The Company also derives revenues from genetic identity and clinical services. There has been a dramatic and constant increase in the number of private paternity cases implemented at the Company and in the number of molecular diagnostic assays performed. The Company designed and implemented molecular diagnostic assays for the presence of DNA attributable to the various human herpes viruses. This platform technology is being used to serve individual patients across the country and in support of an on-going clinical study with a new anti-viral therapeutic. The Company has grown its molecular diagnostic platform in several other critical areas and its services are being used in support of still other on-going clinical trials and in support of fundamental research and development programs for its clients.

Results of Operations

Year Ended December 31, 2003 Compared to Year Ended December 31, 2002.

Revenues

Gross revenues increased by \$669,677 or 15.1% from \$4,434,379 during the year ended December 31, 2002 ("2002") to \$5,104,056 during the year ended December 31, 2003 ("2003").

The Company experiences fluctuations in all revenue categories. Continuation of existing projects, or engagement for future projects is usually dependent upon the customer's satisfaction with the scientific results provided in initial phases of the scientific program. Continuation of existing projects or engagement of future projects also often depends upon factors beyond the Company's control, such as the timing of product development and commercialization programs of the Company's customers. The Company is unable to predict for more than a few months in advance the volume and dollar amount of future projects. The combined impact of commencement and termination of research contracts from several large customers and unpredictable fluctuations in revenue for laboratory services can result in very large fluctuations in financial performance.

Revenues from lab services decreased by \$227,209 or 30.2% from \$753,337 during 2002 to \$526,128 during 2003. This decrease is primarily due to an the effort of the Company to move away from short term work and begin to focus on long-term commercial and government contracts. The Company continues to view lab services as a potential revenue source. However, the Company views commercial and government projects as the more important source of revenue and has continued to focus its efforts on identifying long-term contractual customers.

Revenues realized from various commercial contracts decreased by \$494,183 or 33.1%, from \$1,491,863 during 2002 to \$997,680 during 2003. This decrease is primarily due to (1) work being completed with three major clients and (2) increased focus in government contracts awarded to the Company. Of the \$997,680 in commercial contracts, three major clients represented 37.3%, 14.3% and 11.6%, respectively, of the revenue earned during 2003. The Company will continue to work with these three clients in 2004.

Revenues realized from various government contracts increased by \$1,228,204 or 63.8%, from \$1,925,486 during 2002 to \$3,153,690 during 2003. This increase was primarily due to a new contract that began in early February. Total revenues for this contract were \$1,154,278. It is anticipated that the Company will continue to do work in 2004 under this contract. Revenue from all of the other government contracts is comparable with last year. Revenues recognized from the Illinois Institute of Technology Research Institute (IITRI) subcontract were \$696,381 during 2003. Of the \$696,381, \$218,569 represents revenue from the fifth year of the contract, which was awarded in September 2003. Additional revenues to be recognized for the remainder of the fourth year of the contract in 2004 are \$465,469. Revenues recognized from the second government sponsor for 2002 amounted to \$719,471. This project is expected to be completed in April 2004 with additional revenue of approximately \$78,700 to be received under to the project for the remainder of 2004.

Revenues recognized from a third government sponsor for 2003 amounted to \$799,452. This project was completed in January 2004. The Company anticipates additional contract revenue from this entity in 2004.

Revenues realized from various genetic testing increased by \$96,141 or 71.6%, from \$134,281 during 2002 to \$230,422 during 2003. This increase is a direct result of the continuation of two major contracts to perform genetic identity analysis.

Revenues realized from other genotyping services increased by \$112,138 or 140.6%, from \$79,766 during 2002 to \$191,904 during 2003. This increase is a direct result of the continuation of two major contracts to perform genetic identity analysis.

Cost of Services

Cost of services consists primarily of materials, labor, subcontractor costs and overhead. The cost of services increased by \$157,368 or 4.7% from \$3,371,131 during 2002 to \$3,528,499 during 2003. The cost of services as a percentage of revenue was 69.1% and 75.9% during 2003 and 2002, respectively. This percentage decrease was primarily due to additional expenditures in labor and materials (see below.)

Direct labor costs increased by \$57,448, or 5.3%, from \$1,084,103 during 2002 to \$1,141,551 during 2003.

The costs for direct materials increased by \$110,308, or 13.4%, from \$825,897 during 2002, to \$936,205 during 2003. This increase is directly attributable to the growth in net revenue of the Company.

Overhead cost consists of indirect labor, depreciation, freight charges, repairs and miscellaneous supplies not directly related to a particular project. Total overhead costs decreased by \$20,007 or 1.4%, from \$1,418,701 during 2002 to \$1,438,708 during 2003. This decrease is primarily due to reduced or eliminated production related expenditures,

Sales, General and Administrative

Sales, general and administrative expenses ("SGA") consist primarily of compensation and related costs for administrative, marketing, facility expenditures, professional fees, consulting, taxes, and depreciation. Total SGA costs increased by \$16,930, or 1.2%, from \$1,403,949 during 2002 to \$1,420,879 during 2003. As a percentage of revenue, these costs were 27.8% and 31.7% during 2003 and 2002, respectively.

Total compensation and benefits increased by \$15,439 or 2.9% from \$523,839 during 2002 to \$539,278 during 2003. Costs in compensation remained relatively flat as compared to last year.

Professional fees decreased by \$83,851 or 26.4% from \$317,139 during 2002 to \$233,288 during 2003. This decrease is primarily due to a rate reduction in legal fees and one time consulting costs paid in 2002 that did not occur in 2003. Taxes and Licenses decreased by \$28,564 or 28.3% from \$100,872 during 2002 to \$72,308 during 2003. This decrease is primarily due to a rate reduction in personal property taxes paid to the county. Office expenses increased by \$6,832 or 11.4%, from \$59,918 during 2002 to \$66,750 during 2003. This increase is primarily due to additional office supplies.

Marketing costs increased by \$114,061 or 95.9%, from \$118,889 during 2002 to \$232,950 during 2003. This increase was primarily due to the addition of a Senior Vice President for Strategic Business Development with his focus on building the revenue stream of the Company.

Other Income (Expenses)

Other income increased by \$14,590, or 174.1% from \$8,380 during 2002 to \$22,970 during 2003. This increase is due to a one-time payment from the insurance company for downed equipment due to a power outage.

Interest costs incurred by the Company during the 2003 and 2002 period's included (1) interest paid to financial institutions for loans made to the Company; (2) interest paid for the Company's IRBs; and (3) amortization of costs incurred as a consequence of the completion of the Company's IRB financing. Interest expense decreased by \$35,156 or 12.4% from \$293,405 during 2002 to \$258,249 during 2003.

Results of Operations

Year Ended December 31, 2002 Compared to Year Ended December 31, 2001.

Revenues

Gross revenues decreased by \$351,708 or 7.3% from \$4,786,087 during the year ended December 31, 2001 ("2001") to \$4,434,379 during the year ended December 31, 2002 ("2002").

On April 30, 2001, the Company signed a patent license agreement with Applied Biosystems Group of PE Corporation, New York. This license agreement granted Applied Biosystems a non-exclusive, worldwide, perpetual, non-assignable license under the Patent. This enabled Applied Biosystems to research, develop, make, have made, import, market, use, sell, have sold, offer to sale, distribute, have distributed and otherwise exploit products and services and to pass on to end user customers of Applied Biosystems or its distributors the right to use such product and services. The Company received licensing fees of \$400,000 in the second quarter of 2001, of which \$200,000 was received in cash and the remaining \$200,000 in product and service credits. This impacted favorably on 2001's financial statements. Excluding this one-time license fee, gross revenues increased by \$48,292 or 1.1% from \$4,386,087 during the 2001 Period to \$4,434,379 during the 2002 Period.

Revenues from lab services increased by \$93,604 or 14.2% from \$659,733 during 2001 to \$753,337 during 2002. Over the course of the year, the Company had continued to see growth in one-time orders.

Revenues realized from various commercial contracts decreased by \$293,867 or 16.5%, from \$1,785,730 during 2001 to \$1,491,863 during 2002. The decrease was primarily due to work being completed with four major clients. Of the \$1,491,863 in commercial contracts, two major clients represented 20.7% and 12.8%, respectively, of the revenue earned during 2002.

Revenues realized from various government contracts increased by \$357,371 or 22.8%, from \$1,568,115 during 2001 to \$1,925,486 during 2002. This increase was primarily due to work on three government projects during 2002. Revenues recognized from the IITRI subcontract were \$720,096 during 2002. Of the \$720,096, \$94,741 represents revenue from the fourth year of the contract, which was awarded in September 2002. Additional revenues to be recognized for the remainder of the fourth year of the contract in 2003 are \$392,383. Revenues recognized from the second government sponsor for 2002 amounted to \$719,471. This project was completed in February 2003.

Revenues recognized from a third government sponsor for 2002 amounted to \$288,043. This project was completed in January 2003. Additional funds of approximately \$400,000 have been added to perform additional work in 2003.

Revenues realized from various genetic testing decreased by \$78,931 or 37.0%, from \$213,212 during 2001 to \$134,281 during 2002. This decrease is a direct result of the cancellation of a major contract by a customer who chose to continue the work internally and the cancellation of our marketing efforts due to the cost cutting policy issued by management.

In 2001, under license from a third party, the Company implemented rapid and novel techniques for analysis of patient samples for the presence of residual DNA attributable to the various human herpes viruses.

Revenues realized from this and other genotyping services decreased by \$45,280 or 36.2%, from \$125,046 during 2001 to \$79,766 during 2002. In order to attract new patient work, the Company offers discounts to large clinical practices. In addition, the Company must pay royalties on the technology used.

Revenues realized from license fees in 2002 were \$4,000 as compared to \$402,000 in 2001. As mentioned below, this decrease is a direct result of the one-time license fee paid to the Company.

On April 30, 2001 the Company signed a patent license agreement (U.S. Patent No. 6,110,683 entitled "Automated DNA Sequencer Loading Dye Which Contains A Lane Tracking Aid issued August 29, 2000) with Applied Biosystems Group, an Applied Biosystems Corporation, Foster City, CA. The Company received licensing fees of \$400,000 of which \$200,000 was received in cash in the second quarter and the remaining \$200,000 in product and service credits. These credits were utilized in June and the equipment is fully operational.

In November 2001, the Company signed a license agreement for the *in vitro* use of HepArrest™ with MediRox AB, Linköping, Sweden. This non-exclusive license limits MediRox to the use of HepArrest in its own proprietary diagnostic instruments and obligates MediRox to purchase HepArrest from the Company. MediRox will pay the Company a \$50,000 license fee and is buying HepArrest exclusively from CBI. Depending on how fast MediRox can grow its *in vitro* diagnostic market sales of HepArrest can become a contributing revenue source for the Company.

Cost of Services

Cost of services consists primarily of materials, labor, subcontractor costs and overhead. The cost of services excluding research and development costs, decreased by \$710,701 or 17.4% from \$4,081,832 during 2001 to \$3,371,131 during 2002. The cost of services as a percentage of revenue was 76.0% and 85.3% during 2002 and 2001, respectively. This percentage decrease was primarily due to reduction in costs in direct materials and expenditures in subcontractor costs (see below.)

Direct Labor costs decreased by \$55,768, or 4.9%, from \$1,139,871 during 2001 to \$1,084,103 during 2002. This decrease reflects the cost cutting measures taken by management that included reduced staffing through layoffs and attrition.

The costs for direct materials decreased by \$121,089, or 12.9%, from \$947,706 during 2001, to \$825,897 during 2002. This decrease is directly attributable to more labor-intensive projects obtained by the Company.

Subcontractor costs as of 2001 were \$102,907. These costs incurred were from subcontractors in the new drug development activity that was placed in operation in 2001. There were virtually no subcontract costs in 2002.

Overhead cost consists of indirect labor, depreciation, freight charges, repairs and miscellaneous supplies not directly related to a particular project. Total overhead costs decreased by \$444,486 or 23.9%, from \$1,863,187 during 2001 to \$1,418,701 during 2002. This decrease is primarily due to the following: 1) reduction of salaries that were charged to indirect labor, 2) management reduced staffing through layoffs and attrition and reduced or eliminated production related expenditures, 3) reduced maintenance costs on equipment, and 4) elimination of amortization costs associated with the purchase of contracts in Drug Development.

Research and development costs within the Company fall into two general categories: grant-related research and development and in-house research and development. These categories are distinguished by those performed in support of government grant-sponsored programs, and those performed in the absence of such grants which are funded from working capital. Total expenditures to perform grant-related research activities decreased by \$9,034, or 63.0%, from \$14,348 during 2001 to \$5,314 during 2002. This decrease is primarily due to the Company redirecting its focus on long-term commercial contracts. There were no expenditures made by the Company for in-house research activities. This decision is primarily attributable to the reallocation of all personnel from internal R&D efforts to focus on its core business in contract research.

Sales, General and Administrative

Sales, general and administrative expenses ("SGA") consist primarily of compensation and related costs for administrative, marketing and sales personnel, facility expenditures, professional fees, consulting, taxes, and depreciation. Total SGA costs decreased by \$613,429, or 30.4%, from \$2,017,378 during 2001 to \$1,403,949 during 2002. As a percentage of revenue, these costs were 31.7% and 42.2% during 2002 and 2001, respectively.

Total compensation and benefits decreased by \$80,766 or 13.4% from \$604,606 during 2001 to \$523,839 during 2002. This decrease is attributable to the reduction in administrative staff due to the cost cutting measures implemented by management in 2001.

Facility costs decreased by \$41,581 or 41.1% from \$101,259 during 2001 to \$59,678 during 2002. This decrease is primarily due to the elimination of rent paid for the offices of the drug development division. Depreciation expense decreased by \$45,873 or 31.6%, from \$145,231 during 2001 to \$99,358 during 2002. This decrease is primarily due to the write-off of obsolete equipment in 2001. Taxes and Licenses decreased by \$24,650 or 19.6% from \$125,522 during 2001 to \$100,872 during 2002. This decrease is primarily due to a rate reduction in business taxes, sales taxes and personnel property taxes paid to the state and county in Virginia. Office expenses decreased by \$37,712 or 38.6%, from \$97,630 during 2001 to \$59,918 during 2002. This decrease is primarily due to across the board cuts in all items associated with conducting business in the office. Other costs increased by \$105,973 or 59.7% from \$177,626 during 2001 to \$71,653 during 2002. This decrease is primarily due to the difference in bad debt write-offs in 2001 that did not happen in 2002.

Marketing costs decreased by \$215,616 or 64.5%, from \$334,505 during 2001 to \$118,889 during 2002. Based on management's decision to control expenditures, there was virtually no advertising done during the 2002 Period. Whereas during the 2001 Period, the Company opted to increase its marketing exposure throughout the marketplace with major increases in advertising and public relations.

Other Income (Expense)

Interest income decreased by \$68,034, or 89.0% from \$76,414 during 2001 to \$8,380 during 2002. This decrease is due to the lack of investment income.

Interest costs incurred by the Company during the 2002 and 2001 Period's included (1) interest paid to financial institutions for loans made to the Company; (2) interest paid for the Company's IRBs; and (3) amortization of costs incurred as a consequence of the completion of the Company's IRB financing. Interest expense increased by \$10,281 or 3.6% from \$283,124 during 2001 to \$293,405 during 2002.

Liquidity and Capital Resources

The 2003 Period reflected cash provided by from operating activities of \$248,625, as compared to \$242,912 during the 2002 Period. This was primarily due to the decrease in net loss, offset by an increase in accounts receivable of 307,418.

The 2003 Period reflected a use of cash from financing activities of \$174,153, as compared to \$57,395 during the 2002 Period. The 2002 Period included net proceeds from issuance of stock of \$248,000 versus \$2,000 in the current year.

Net working capital as of December 31, 2003 and December 31, 2002 was \$575,919 and \$86,701, respectively. This increase is a direct result of increase in cash and accounts receivables as well as a reduction in outstanding payables.

In the fourth quarter of 1999, the Company was awarded a five-year subcontract with the Illinois Institute of Technology Research Institute. The contract is valued at approximately \$8.5 million. During the fourth Quarter in 2003, the fifth year of this contract was awarded amounting to \$696,381 to the Company. In March 2004, the Company received approval of additional funding from the customer in the amount of \$769,375 for a project that will be completed during the second quarter of 2004.

In September 2003, the Company received approval to begin working on a project from an existing client in the amount of \$452,148. Since the inception of this project, the Company has recognized \$22,579. Work on project will be done over a five-month period.

In March 2004, the Company received approximately \$546,000 from the sale of ISO's. These ISO's were exercised both from management and employees of the Company. Therefore, the Company believes that the cash flow from operations is expected to be sufficient to cover operating expenses for the current fiscal year.

Critical Accounting Policies

A summary of the Company's accounting policies follows:

Estimates: The preparation of the financial statements requires management to make estimates and assumptions that affect the reported amounts of asset and liabilities and disclosure of contingent asset and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.

Revenue Recognition: The Company recognizes revenue upon the completion of laboratory service projects, or upon the delivery and acceptance of biologically relevant materials that have been synthesized in accordance with project terms. Laboratory service projects are generally administered under fee for service contracts. Any revenues from research and development arrangements, including corporate contracts and research grants, are recognized pursuant to the terms of the related agreements as work is performed, or scientific milestones, if any are achieved. Amounts received in advance of the performance of services or acceptance of a milestone, are recorded as deferred revenue.

Accounts receivable: Accounts receivable are carried at original invoice amount less an estimate for doubtful receivables based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer's financial condition, credit history, and current economic conditions. Accounts receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received.

CBI has met the SEC and NASDAQ Corporate Governance Rules.

As a consequence of the Sarbanes-Oxley Act, the NASDAQ imposed certain changes in the rules of corporate governance which are aimed at strengthening its listing standards. The Securities and Exchange Commission (SEC) approved the rules imposed by NASDAQ which include

- Independent Directors. CBI's Board is composed of 4 independent and 3 employee directors.
- The Independent Directors serve on the three principal committees; Audit, Compensation and Nominations.
- The Independent Directors meet in executive session at each quarterly Board meeting.
- At least one Independent Director, Mr. Sam Sears, who serves on the Audit Committee, meets all of the requirements as defined by the SEC for being a "financial expert."

-
- The Audit Committee reviews and approves all related-party transactions. CBI has adapted a formal Corporate Code of Conduct. Copies are available on request from Dr. Robert B. Harris, President and Chief Executive Officer, and on the Company's website at www.cbi-biotech.com.

Forward Looking Statements

Management has included herein certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used, statements that are not historical in nature, including the words "anticipated", "estimate", "should", "expect", "believe", "intend", and similar expressions are intended to identify forward-looking statements. Such statements are, by their nature, subject to certain risks and uncertainties.

Among the factors that could cause the actual results to differ materially from those projected are the following:

- business conditions and the general economy,
- the development and implementation of the Company's long-term business goals,
- federal, state, and local regulatory environment,
- lack of demand for the Company's services,
- the ability of the Company's customers to perform services similar to those offered by the Company "in-house,"
- potential cost containment by the Company's customers resulting in fewer research and development projects,
- the Company's ability to receive accreditation to provide various services, including, but not limited to paternity testing, and
- the Company's ability to hire and retain highly skilled employees,

Other risks, uncertainties, and factors that could cause actual results to differ materially from those projected are detailed from time to time in reports filed by the company with the Securities and Exchange Commission, including Forms 8-K, 10-QSB, and 10-KSB.

ITEM 3. CONTROLS AND PROCEDURES

The Company's Chief Executive Officer and Controller (principal executive officer and principal financial officer, respectively) have concluded, based on their evaluation as of December 31, 2003, that the design and operation of the Company's "disclosure controls and procedures" (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended ("Exchange Act")) are effective to ensure that information required to be disclosed by the Company in the reports filed or submitted by the Company under the Exchange Act is accumulated, recorded, processed, summarized and reported to management, including the Company's principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding whether or not disclosure is required.

During the quarter ended December 31, 2003, there were no changes in the Company's "internal controls over financial reporting" (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect the Company's internal controls over financial reporting.

Commonwealth Biotechnologies, Inc.

**Financial Statements
Years Ended December 31, 2003 and 2002**

Report of Independent Certified Public Accountants	20 – 21
Financial Statements	
Balance Sheets	22 -23
Statements of Operations	24
Statements of Changes in Stockholders' Equity	25
Statements of Cash Flows	26
Summary of Significant Accounting Policies	27 – 31
Notes to Financial Statements	32 – 37

Report of Independent Certified Public Accountants

Board of Directors and Stockholders
Commonwealth Biotechnologies, Inc.
Richmond, Virginia

We have audited the accompanying balance sheet of Commonwealth Biotechnologies, Inc. as of December 31, 2003 and the related statement of operations, changes in stockholders' equity, and cash flows for the year then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform our audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Commonwealth Biotechnologies, Inc. at December 31, 2003, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

/s/ BDO SEIDMAN, LLP
January 23, 2004

McGladrey & Pullen
Certified Public Accountants

Independent Auditor's Report

To the Board of Directors and Stockholders
Commonwealth Biotechnologies, Inc.
Richmond, Virginia

We have audited the accompanying balance sheet of Commonwealth Biotechnologies, Inc. as of December 31, 2002 and the related statements of operations, changes in stockholders' equity, and cash flows for the year then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Commonwealth Biotechnologies, Inc. as of December 31, 2002, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

The accompanying 2002 financial statements have been prepared assuming the Company will continue as a going concern. The Company's significant operating losses and negative cash flows raise substantial doubt about its ability to continue as a going concern. The 2002 financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ McGladrey & Pullen, LLP

Richmond, Virginia
February 18, 2003

Commonwealth Biotechnologies, Inc.

Balance Sheets

December 31,

2003

2002

Assets	2003	2002
Current assets		
Cash and cash equivalents	\$ 294,922	\$ 270,144
Accounts receivable, net of allowance for doubtful accounts of approximately \$71,000 and \$69,000 (Note 6)	799,981	492,563
Prepaid expenses and other current assets	60,936	75,980
Total current assets	1,155,839	838,687
Property and equipment, net (Notes 1 and 3)	5,649,657	6,198,728
Other assets		
Bond issuance costs, less accumulated amortization 2003 – \$62,137; 2002 – \$51,393	206,462	217,205
Restricted cash (Note 3)	569,255	568,453
Total other assets	775,717	785,658
	\$ 7,581,213	\$ 7,823,073

See accompanying summary of accounting policies and notes to financial statements.

Commonwealth Biotechnologies, Inc.

Balance Sheets
(continued)

December 31,

	2003	2002
Liabilities and Stockholders' Equity		
Current liabilities		
Current maturities of long-term debt (Note 3)	\$ 100,000	\$ 160,311
Accounts payable and other current liabilities	241,769	259,536
Interest payable	90,596	96,324
Deferred compensation	133,259	136,288
Deferred revenue	14,296	84,847
Demand note payable (Note 2)	—	14,680
Total current liabilities	579,920	751,986
Long-term debt , less current maturities (Note 3)	3,630,000	3,730,000
Total liabilities	4,209,920	4,481,986
Commitments and contingencies (Notes 4 and 5)		
Stockholders' equity		
Common stock, no par value, 10,000,000 shares authorized, 2003 – 2,534,928; 2002 – 2,433,779, shares issued and outstanding	—	—
Additional paid-in capital	12,315,806	12,204,999
Accumulated deficit	(8,944,513)	(8,863,912)
Total stockholders' equity	3,371,293	3,341,087
	\$ 7,581,213	\$ 7,823,073

See accompanying summary of accounting policies and notes to financial statements.

Commonwealth Biotechnologies, Inc.

Statements of Operations

Year Ended December 31,

	2003	2002
Revenues (Note 6)		
Government contracts	\$3,153,690	\$1,925,486
Commercial contracts	997,680	1,491,863
Laboratory services	526,128	753,337
Genetic identity	230,422	134,281
Clinical services	191,904	79,766
Other revenue	4,232	49,646
Total revenues	5,104,056	4,434,379
Cost of services		
Overhead	1,438,708	1,418,701
Direct labor	1,141,551	1,084,103
Direct materials	936,205	825,897
Other direct costs	12,035	42,430
Total cost of services	3,528,499	3,371,131
Gross profit	1,575,557	1,063,248
Selling, general and administrative	1,420,879	1,403,949
Operating income (loss)	154,678	(340,701)
Other income (expense)		
Interest expense	(258,249)	(293,405)
Other income	22,970	8,380
Total other income (expense)	(235,279)	(285,025)
Net loss	\$ (80,601)	\$ (625,726)
Loss per common share, basic and diluted	\$ (0.03)	\$ (0.29)

See accompanying summary of accounting policies and notes to financial statements.

Commonwealth Biotechnologies, Inc.
Statements of Changes in Stockholders' Equity

	Number of Shares Outstanding	Additional Paid-in Capital	Accumulated Deficit	Total
Balance, December 31, 2001	2,076,164	\$ 11,892,955	\$(8,238,186)	\$ 3,654,769
Issuance of common stock	357,615	366,500	—	366,500
Issuance costs	—	(54,456)	—	(54,456)
Net loss	—	—	(625,726)	(625,726)
Balance, December 31, 2002	2,433,779	12,204,999	(8,863,912)	3,341,087
Issuance of common stock	101,149	110,807	—	110,807
Net loss	—	—	(80,601)	(80,601)
Balance, December 31, 2003	2,534,928	\$ 12,315,806	\$(8,944,513)	\$ 3,371,293

See accompanying summary of accounting policies and notes to financial statements.

Commonwealth Biotechnologies, Inc.

Statements of Cash Flows

Year Ended December 31,

	2003	2002
Operating activities		
Net loss	\$ (80,601)	\$(625,726)
Adjustments to reconcile net loss to cash provided by (used in) operating activities		
Depreciation and amortization	609,508	631,730
Issuance of stock in lieu of board fees	109,167	64,500
Changes in assets and liabilities		
Accounts receivable	(307,418)	138,726
Prepaid expenses	15,045	(6,374)
Accounts payable	(26,525)	(8,526)
Deferred revenue	(70,551)	48,582
Cash provided by operating activities	<u>248,625</u>	<u>242,912</u>
Investing activities		
Purchases of property and equipment	(49,694)	(31,524)
Cash used in investing activities	<u>(49,694)</u>	<u>(31,524)</u>
Financing activities		
Increase in restricted cash	(802)	(52,920)
Principal payments on debt obligations, including capital lease obligations	(174,991)	(252,019)
Proceeds from issuance of common stock	1,640	247,544
Cash used in financing activities	<u>(174,153)</u>	<u>(57,395)</u>
Net increase in cash and cash equivalents	24,778	153,993
Cash and cash equivalents, beginning of year	270,144	116,151
Cash and cash equivalents, end of year	\$ 294,922	\$ 270,144
Supplemental Disclosure of Cash Flow Information		
Cash payments for interest	<u>\$ 247,505</u>	<u>\$ 262,480</u>

See accompanying summary of accounting policies and notes to financial statements.

Nature of Business

Commonwealth Biotechnologies, Inc., (the "Company"), was formed on September 30, 1992, for the purpose of providing specialized analytical laboratory services for the life scientist. The Company provides basic research services in the general areas of protein/peptide and DNA/RNA chemistries. Such services include synthesis, sequence analysis, composition analysis, protein purification and biophysical characterization of biologically relevant materials. The Company also pursues its own research and development leading to intellectual properties.

Estimates

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent asset and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.

Revenue Recognition

The Company recognizes revenue upon the completion of laboratory service projects, or upon the delivery and acceptance of biologically relevant materials that have been synthesized in accordance with project terms. Laboratory service projects are generally administered under fee-for-service contracts or purchase orders. Any revenues from research and development arrangements, including corporate contracts and research grants, are recognized pursuant to the terms of the related agreements as work is performed, or as scientific milestones, if any, are achieved. Amounts received in advance of the performance of services or acceptance of a milestone, are recorded as deferred revenue.

Long-Lived Assets

Long-lived assets, such as property, plant, and equipment, are evaluated for impairment when events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable through the estimated undiscounted future cash flows from the use of those assets. When any such impairment exists, the related assets will be written down to fair value. No impairment losses have been recorded through December 31, 2003.

Cash and Cash Equivalents

The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. At times, the Company maintains cash balances in excess of FDIC insured amounts. As of December 31, 2003, the excess over the FDIC amount was \$101,596.

Accounts Receivable

Accounts receivable are carried at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivable and considering a customer's financial condition, credit history, and current economic conditions. Accounts receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received.

Property and Equipment

Property and equipment are recorded at cost. Depreciation is computed principally by the straight-line method over the following estimated useful lives providing depreciation and amortization for financial reporting purposes. The cost of repairs and maintenance is expensed as incurred. The estimated useful lives of the assets are as follows:

	<u>Years</u>
Buildings	39.5
Laboratory and computer equipment	3 – 10
Furniture and fixtures and office equipment	7
Automobile	5

Other Assets

Bond issuance costs consist of origination cost associated with the 2000 bond issue and are being amortized over twenty-five years using the straight-line method, which does not differ materially from the effective interest method. Amortization expense was \$10,744 for the years ended December 31, 2003 and 2002.

Income Taxes

Deferred taxes are provided on an asset and liability method whereby deferred tax assets are recognized for deductible temporary differences and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Loss Per Common Share

Basic loss per share has been computed on the basis of the weighted-average number of common shares outstanding. Common shares issuable upon exercise of stock options and warrants (see Note 8) have not been included in the computation because their inclusion would have been antidilutive. Weighted average shares outstanding for basic and diluted loss per common share were 2,486,699 and 2,194,029 for the years ended December 31, 2003 and 2002, respectively.

Employee Stock Plans

The Company adopted a Stock Incentive Plan on June 24, 1997. The Plan provides for granting to employees, officers, directors, consultants and certain other nonemployees of the Company options to purchase shares of common stock. A maximum of 410,000 shares of common stock may be issued pursuant to the Plan. Of the maximum number of shares to be issued under the Plan, 270,000 have been reserved for incentive awards to be granted to the founders of the Company, and 61,000 are reserved for incentive awards to be granted to others.

Employee Stock Plans (continued)

A 2002 Stock Incentive Plan was adopted by the Board of Directors and approved by the shareholders. The Plan makes up to 300,000 shares of common stock available for grants of restricted stock awards and stock options in the form of incentive stock options and non-qualified options to employees, directors and consultants of the Company.

Incentive awards may be in the form of stock options, restricted stock, incentive stock or tax offset rights. In the case of incentive stock options (within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended), the exercise price will not be less than 100% of the fair market value of shares covered at the time of the grant, or 110% for incentive stock options granted to persons who own more than 10% of the Company's voting stock. Options granted under the Plans generally vest over a five-year period from the date of grant and are exercisable for ten years, except that the term may not exceed five years for incentive stock options granted to persons who own more than 10% of the Company's outstanding common stock.

The Company applies Accounting Principles Board Opinion No. 25 and related accounting interpretations in accounting for its plan and for management warrants and, accordingly, no compensation cost has been recognized. Had compensation cost for the Company's plan been determined based on the fair value at the grant dates for awards under the plan consistent with the method prescribed by FASB No. 123, *Accounting for Stock-Based Compensation*, the Company's net loss and loss per share would have increased to the proforma amounts indicated below:

	2003	2002
Net loss		
As reported	\$ (80,601)	\$(625,726)
Proforma effect of recognizing stock-based compensation in accordance with FASB No. 123	(101,115)	(132,644)
Proforma	(181,716)	(758,370)
Basic and diluted loss per common share		
As reported	(0.03)	(0.29)
Proforma	(0.07)	(0.35)

Under FASB No. 123, the fair value of each management stock option and warrant is estimated on the date of grant using the Black-Scholes option pricing model. The following weighted-average assumptions were used for grants in 2003 and 2002, respectively: No dividend yield, expected volatility of 144% and 138%, risk-free interest rate of 4.38% and 1.2%, and expected lives of 10 years.

Fair Value of Financial Instruments

The Company has determined, based on available market information and appropriate valuation methodologies, that the fair value of its financial instruments approximates carrying value. The carrying amounts of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to the short-term maturity of the instruments. The carrying amount of debt approximates fair value because the interest rates under the credit agreement are predominantly variable, based on current market conditions.

Reclassifications

Certain amounts in the 2002 financial statements have been reclassified to conform to the 2003 financial statement presentation. The reclassifications had no effect on either net income or retained earnings for the year ended December 31, 2002.

New Accounting Pronouncements

In October 2001, the FASB issued SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets" ("SFAS 144"). This statement addresses financial accounting and reporting for the impairment or disposal of long-lived assets. This statement supersedes FASB Statement No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of", and the accounting and reporting provisions of APB Opinion No. 30, "Reporting the Results of Operations — Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions". This statement also amends ARB No. 51, "Consolidated Financial Statements", to eliminate the exception to consolidation for a subsidiary for which control is likely to be temporary. This statement requires that one accounting model be used for long-lived assets to be disposed of by sale, whether previously held and used or newly acquired. This statement also broadens the presentation of discontinued operations to include more disposal transactions. SFAS 144 is effective for fiscal years beginning after December 15, 2001 and interim periods within those fiscal years. The adoption of SFAS 144 did not have an impact on the Company's financial position and results of operations.

In June 2002, the Financial Accounting Standards board issued Statement No. 146, Accounting for Costs Associated with Exit or Disposal Activities (SFAS 146). This Statement addresses financial accounting and reporting for costs associated with exit or disposal activities and nullifies Emerging Issues Task Force (EITF) Issue No. 94-3, "Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity (including Certain Costs Incurred in a Restructuring)." The principal difference between this Statement and Issue 94-3 relates to its requirements for recognition of a liability for a cost associated with an exit or disposal activity. This Statement requires that a liability for a cost associated with an exit or disposal activity be recognized when the liability is incurred. Under Issue 94-3, a liability for an exit cost as defined in Issue 94-3 was recognized at the date of an entity's commitment to an exit plan. A fundamental conclusion reached by the Board in this Statement is that an entity's commitment to a plan, by itself, does not create a present obligation to others that meets the definition of a liability. Therefore, this Statement eliminates the definition and requirements for recognition of exit costs in Issue 94-3. This Statement also establishes that fair value is the objective for initial measurement of the liability. The provisions of this Statement are effective for exit or disposal activities that are initiated after December 31, 2002. The adoption of SFAS 146 did not have a material impact on the Company's financial statement.

New Accounting Pronouncements (continued)

In November 2002, the FASB issued Interpretation No. 45, "Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness to Others", an interpretation of FASB Statements No. 5, 57 and 107 and a rescission of FASB Interpretation No. 34. This Interpretation elaborates on the disclosures to be made by a guarantor in its interim and annual financial statements about its obligations under guarantees issued. The Interpretation also clarifies that a guarantor is required to recognize, at inception of a guarantee, a liability for the fair value of the obligation undertaken. The initial recognition and measurement provisions of the Interpretation are applicable to guarantees issued or modified after December 31, 2002 and are not expected to have a material effect on the Company's financial statements. The disclosure requirements are effective for financial statements of annual periods ending after December 15, 2002 and the adoption of No. 45 Interpretation does not have any impact on recognition of liabilities and any material impact on the disclosures.

In December 2002, the FASB issued SFAS No. 148, "Accounting for Stock-Based Compensation – Transition and Disclosure – an amendment of FASB Statement No. 123". This Statement amends FASB Statement No. 123, "Accounting for Stock-Based Compensation", to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, this Statement amends the disclosure requirements of Statement 123 to require prominent disclosures in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method used on reported results. The Company does not expect the adoption of SFAS 148 to have an effect on the Company's financial statements.

In May 2003, the FASB issued SFAS No. 150, "Accounting for Certain Financial Instruments with Characteristics of Both Liabilities and Equity" (SFAS 150). This Statement establishes standards for how an issuer classifies and measures certain financial instruments with characteristics of both liabilities and equity. This Statement requires many instruments previously classified as equity to be classified as liabilities. Such as mandatorily redeemable shares and repurchase obligations related to an issuer's equity shares. This Statement is effective for nonpublic entities for financial instruments entered into or modified after May 31, 2003 and otherwise is effective for fiscal periods beginning after December 15, 2004 for instruments that are mandatorily redeemable on fixed dates for amounts that are fixed or determinable. The Company does not expect the adoption of SFAS 150 to have a material impact on the financial statements.

In December 2003, the FASB issued a revised Interpretation No. 46, "Consolidation of Variable Interest Entities (VIE)", which clarifies the application of ARB No. 51 and replaces Interpretation No. 46. This Interpretation addresses the consolidation by business enterprises of variable interest entities as defined in the Interpretation. A nonpublic enterprise shall apply this Interpretation to all entities that are subject to this Interpretation by the beginning of the first annual period beginning after December 15, 2004. The Interpretation requires certain disclosures in financial statements issued after December 31, 2003 if it is reasonably possible that the Company will consolidate or disclose information about variable interest entities when the Interpretation becomes effective. The Company does not believe that it has any VIE for consolidation.

1. Property and Equipment

Property and equipment consisted of the following:

<i>December 31,</i>	2003	2002
Land	\$ 403,919	\$ 403,919
Building	4,904,666	4,904,666
Laboratory equipment	3,383,151	3,359,189
Furniture, fixtures and office and computer equipment	423,796	398,074
	9,115,532	9,065,848
Less accumulated depreciation	3,465,875	2,867,120
	\$ 5,649,657	\$ 6,198,728

Depreciation expense was \$598,765 and \$620,986 for the years ended December 31, 2003 and 2002, respectively.

2. Demand Notes Payable

At December 31, 2002, the Company had a demand note payable with a bank, bearing interest at the prime rate plus 1%. The note was paid in full in March 2003.

3. Long-Term Debt

Long-term debt consist of:

<u>December 31,</u>	<u>2003</u>	<u>2002</u>
Industrial Revenue Development Bonds Series 1998A (5.2% - 7%), payable in monthly installments of interest only through March 15, 2000, annual installments of principal and interest from March 15, 2001 through March 15, 2023, secured by a first deed of trust on land and building.	\$ 3,400,000	\$ 3,495,000
Industrial Revenue Development Bonds Series 1998B (8%), payable in monthly installments of interest only through March 15, 2023 and a final payment of \$330,000 due March 15, 2023, secured by a second deed of trust on land and building.	330,000	330,000
Capital lease obligation due in monthly installments of \$8,502 to August 2003, discounted at a rate of 10.9%	—	65,311
	3,730,000	3,890,311
Less current maturities	100,000	160,311
	\$ 3,630,000	\$ 3,730,000

Scheduled maturities of long-term debt are as follows:

2004	\$ 100,000
2005	105,000
2006	110,000
2007	115,000
2008	125,000
Thereafter	3,175,000
	\$3,730,000

The bond agreements require the Company to maintain debt service reserve funds, which are held by a trustee. Debt service reserve funds are included in the balance sheets as restricted cash.

4. Leasing Commitments

The Company leases equipment under noncancelable operating leases. Total expense for the years ended December 31, 2003 and 2002 was \$42,800 and \$48,000, respectively. Future minimum rental commitments under operating leases as of December 31, 2003 are as follows:

2004	\$42,600
2005	35,500
2006	10,900
2007	3,600
	<u>\$92,600</u>

5. Retirement Plan

The Company maintains a 401(k) Plan (the "Plan") which covers substantially all employees. Under the Plan, employees may elect to defer a portion of their salary, up to the maximum allowed by law, and the Company can elect to match the contribution up to 1% of the employee's salary. No Company contributions were made to the Plan in 2003 or 2002.

6. Major Customers

Revenues for the years ended December 31, 2003 and 2002 include revenues from two major customers of approximately \$1,154,000 or 23% of total revenues and \$1,125,000 or 25% of total revenues, respectively. Trade receivables due from these customers as of December 31, 2003 and 2002 were \$365,000 and \$135,000, respectively.

7. Income Taxes

The difference between expected income tax benefits and income tax benefits recorded in the financial statements is explained below:

<u>December 31,</u>	<u>2003</u>	<u>2002</u>
Income taxes (benefit) computed at 34% statutory rate	\$(27,400)	\$(212,747)
State income tax benefit, net	(4,200)	(22,600)
Change in valuation allowance	26,200	272,951
Other	5,400	(37,604)
	<u>\$ —</u>	<u>\$ —</u>

7. Income Taxes (continued)

The significant components of deferred income tax assets and liabilities as of December 31, 2003 consist of the following:

<u>December 31,</u>	<u>2003</u>	<u>2002</u>
Deferred tax assets		
Net operating loss carryforward	\$ 3,499,000	\$ 3,519,026
Research and development credit carryforward	52,600	52,564
Deferred compensation	50,600	52,000
Other	40,600	93,331
	<u>3,642,800</u>	<u>3,716,921</u>
Deferred tax liabilities		
Tax depreciation in excess of book depreciation	359,300	407,250
	<u>3,283,500</u>	<u>3,309,671</u>
Net deferred tax asset before valuation allowance	3,283,500	3,309,671
Less valuation allowance	3,283,500	3,309,671
	<u>\$ —</u>	<u>\$ —</u>

Operating loss carryforwards of approximately \$9,176,000 may be used to offset future taxable income and expire in various years through 2023. The Company also has research and development credit carryforwards of approximately \$53,000 that expire in various years through 2020.

8. Stock Compensation

In addition to employee stock option awards, the Company has reserved an aggregate of 383,889 shares of common stock for issuance upon exercise. Management warrants (100,000), warrants issued in connection with the 2000 private placement (174,000), warrants issued in connection with the 2002 private placement (83,889) and the Retainer and Transaction Fee Warrants (200,000) (see Note 9). During 2003, the Company issued 70,704 shares of common stock in lieu of directors fees.

Stock option transactions are summarized as follows:

	2003	Weighted Average Exercise Price	2002	Weighted Average Exercise Price
Options and warrants outstanding, beginning of year	1,266,817	\$ 5.05	958,047	\$ 6.49
Granted	51,700	3.02	336,821	0.97
Exercised	(30,445)	.90	—	—
Expired	(101,500)	6.50	(28,051)	4.90
Options and warrants outstanding, end of year	<u>1,186,572</u>	<u>5.03</u>	<u>1,266,817</u>	<u>\$ 5.09</u>
Options and warrants exercisable, end of year	<u>979,322</u>	<u>4.76</u>	<u>813,565</u>	<u>\$ 5.91</u>
Weighted-average fair value per option and warrants for options and warrants granted during the year		<u>\$ 1.96</u>		<u>\$ 0.70</u>

The following table summarizes information about stock options and warrants outstanding at December 31, 2003:

Exercise Prices Per Share	Outstanding			Exercisable	
	Number Outstanding	Weighted Average Remaining Contractual Life (Years)	Weighted Average Exercise Price Per Share	Number Exercisable	Weighted Average Exercise Price Per Share
\$0.85 – 1.50	312,076	8	\$.98	309,426	\$.98
\$2.42 – 5.25	369,777	7	3.91	343,277	3.95
\$5.50 – 7.00	225,363	3	6.36	48,613	5.90
\$7.50 – 9.00	21,300	6	7.61	19,950	7.59
\$9.25 – 10.00	257,356	4	9.89	257,356	9.89
\$19.00 – 20.00	700	6	20.00	700	20.00
<u>\$0.85 – 20.00</u>	<u>1,186,572</u>		<u>\$ 5.03</u>	<u>979,322</u>	<u>\$ 4.76</u>

9. Engagement of Segerdahl and Company, Inc.

The Company had engaged Segerdahl and Company, Inc. ("Segerdahl") an investment banking firm, to provide the Company with investment banking services. The agreement was signed on April 22, 2002 and was for a term of one year and was subsequently extended to October 1, 2003, at which time it was not renewed.

In connection with the agreement, the Company issued to Segerdahl a three year warrant, as amended, to purchase 100,000 shares of the Company's common stock at an exercise price of \$0.90 per share (the "Retainer Warrant"). The warrants vested in 2002. The expense related to the warrants was not material.

In addition, as a transaction fee, the Company issued to Segerdahl a three year warrant, as amended, to purchase 100,000 shares of the Company's common stock at an exercise price of \$0.90 per share (the "Transaction Fee Warrant"). The Transaction Fee Warrant will only vest in the event (i) the Company completes a Transaction as defined in the agreement, and (ii) the Company's common stock trades at a price per share at or above \$2.90 per share for 10 of 20 consecutive trading days during the term of the engagement. The warrants had not vested as of December 31, 2003.

10. Private Placement Offering

On August 30, 2002, the Company completed a private placement of 335,555 shares of common stock at a purchase price of \$.90 per share and warrants to purchase an additional 83,889 shares of common stock. Each warrant gives the holder the right to purchase one share of common stock at a price of \$.90 per share for a period of 10 years. The warrants are callable at the option of the Company at a price of \$.90 each. As of December 31, 2003 and 2002, no warrants have been exercised. Proceeds, net of issuance costs, totaled \$247,544.

Corporate Information

Corporate Office

Commonwealth Biotechnologies, Inc.

601 Biotech Drive
Richmond, VA 23235
Telephone: 800-735-9224; 804-648-3820
Fax: 804-648-2641
E-mail: info@cbi-biotech.com
Web site: www.cbi-biotech.com

General Counsel

Kaufman and Canoles, PC
1051 E. Cary St
3 James Center
Richmond, VA 23219

Executive Officers and Board of Directors

Executive Officers

Richard J. Freer, Ph.D.

Chairman of the Board, COO

Thomas R. Reynolds

Executive Vice President and Secretary

Directors

Richard J. Freer, Ph.D.

Chairman of the Board, COO

Thomas R. Reynolds

Executive Vice President and Secretary

James Causey

Consultant

Peter Einselen

Broker
Anderson and Strudwick, Inc.

Patent Counsel

Bums Doan Swecker and Mathis, LLP
1737 King Street
Alexandria, VA 22314

Transfer Agent and Registrar

Computershare Trust Co.
350 Indiana St.
Golden, CO 80401

Independent Auditors

BDO Seidman, LLP
300 Arboretum Place
Suite 520
Richmond, VA 23236

Robert B. Harris, Ph.D.

President, CEO

James H. Brennan, MBA

Controller

Robert B. Harris, Ph.D.

President, CEO

Samuel P. Sears, Jr.

Attorney at Law

Donald A. McAfee, Ph.D.

Chief Technical Officer
Aderis Pharmaceuticals, Inc.

Independent Auditor's Consent

As independent auditors, we hereby consent to the incorporation by reference of our report, dated February 18, 2003, which includes an emphasis paragraph relating to uncertainty as to the Company's ability to continue as a going concern, relating to the financial statements of Commonwealth Biotechnologies, Inc. for the year ended December 31, 2002, included in the 2002 Annual Report to Shareholders and incorporated by reference into the Annual Report on Form 10-KSB, into the Company's previously filed Form S-8 Registration Statement, File No. 333-51074, and Form S-3 Registration Statement No. 333-51078.

/s/ McGladrey & Pullen, LLP

Richmond, Virginia
March 30, 2004

CERTIFICATION

I, Robert B. Harris, Ph.D., certify that:

1. I have reviewed this Annual Report on Form 10-KSB of Commonwealth Biotechnologies, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;
4. The small business issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the small business issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

-
- (d) Disclosed in this report any change in the small business issuer's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer's internal control over financial reporting; and
5. The small business issuer's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer's auditors and the audit committee of the small business issuer's board of directors (or persons performing the equivalent functions):
- (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer's ability to record, process, summarize and report financial information; and
- (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer's internal control over financial reporting.

Date: March 30, 2004

/s/ Robert B. Harris, Ph.D.

Robert B. Harris, Ph.D.
President and Chief Executive Officer

CERTIFICATION

I, James H. Brennan, certify that:

1. I have reviewed this Annual Report on Form 10-KSB of Commonwealth Biotechnologies, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;
4. The small business issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the small business issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

-
- (d) Disclosed in this report any change in the small business issuer's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer's internal control over financial reporting; and
5. The small business issuer's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer's auditors and the audit committee of the small business issuer's board of directors (or persons performing the equivalent functions):
- (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer's ability to record, process, summarize and report financial information; and
- (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer's internal control over financial reporting.

Date: March 30, 2004

/s/ James H. Brennan

James H. Brennan
Controller

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Commonwealth Biotechnologies, Inc. (the "Company") on Form 10-KSB for the period ending December 31, 2003 as filed with the Securities and Exchange Commission on March 30, 2004 (the "Report"), I Robert B. Harris, Ph.D., President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

March 30, 2004

/s/ Robert B. Harris, Ph.D.

Robert B. Harris, Ph.D.
President and Chief Executive Officer

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Commonwealth Biotechnologies, Inc. (the "Company") on Form 10-KSB for the period ending December 31, 2003 as filed with the Securities and Exchange Commission on March 30, 2004 (the "Report"), I, James H. Brennan, Controller of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

March 30, 2004

/s/ James H. Brennan

James H. Brennan
Controller